Humanigen, Inc.

Humanigen, Inc.verified

HGEN

Price:

$0.0002

Market Cap:

$23.82K

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ‘cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Dis...[Read more]

Industry

Biotechnology

IPO Date

2013-01-31

Stock Exchange

NASDAQ

Ticker

HGEN

The PE Ratio as of June 2024 (TTM) for Humanigen, Inc. (HGEN) is -0.00

According to Humanigen, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.00. This represents a change of -99.92% compared to the average of -0.46 of the last 4 quarters.

Humanigen, Inc. (HGEN) Historical PE Ratio (quarterly & annually)

How has HGEN PE Ratio performed in the past?

The mean historical PE Ratio of Humanigen, Inc. over the last ten years is -2.68. The current -0.00 PE Ratio has changed -98.54% with respect to the historical average. Over the past ten years (40 quarters), HGEN's PE Ratio was at its highest in in the December 2022 quarter at 0.41. The PE Ratio was at its lowest in in the March 2019 quarter at -15.16.

Quarterly (TTM)
Annual

Average

-2.68

Median

-2.03

Minimum

-7.12

Maximum

-0.10

Humanigen, Inc. (HGEN) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Humanigen, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 1.93%

Maximum Annual PE Ratio = -0.10

Minimum Annual Increase = -88.85%

Minimum Annual PE Ratio = -7.12

Quarterly (TTM)
Annual
YearPE RatioChange
2022-0.10-88.85%
2021-0.91-87.20%
2020-7.1251.28%
2019-4.71-14.84%
2018-5.531.93%
2017-0.27-80.56%
2016-1.40-49.06%
2015-2.7583.19%
2014-1.50-41.29%
2013-2.56258.56%

Humanigen, Inc. (HGEN) Average PE Ratio

How has HGEN PE Ratio performed in the past?

The current PE Ratio of Humanigen, Inc. (HGEN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-2.71

5-year avg

-3.67

10-year avg

-2.68

Humanigen, Inc. (HGEN) PE Ratio vs. Peers

How is HGEN’s PE Ratio compared to its peers?

Humanigen, Inc.’s PE Ratio is less than Acer Therapeutics Inc. (0), greater than NRx Pharmaceuticals, Inc. (-0.27), greater than Pasithea Therapeutics Corp. (-1.05), greater than SAB Biotherapeutics, Inc. (-0.33), greater than Windtree Therapeutics, Inc. (-0.70), greater than Dermata Therapeutics, Inc. (-0.27), greater than Ensysce Biosciences, Inc. (-0.13), greater than Panbela Therapeutics, Inc. (-0.27), greater than Baudax Bio, Inc. (-0.05), greater than Avenue Therapeutics, Inc. (-0.02), greater than Hoth Therapeutics, Inc. (-0.29), greater than Revelation Biosciences, Inc. (-0.52), greater than NeuroBo Pharmaceuticals, Inc. (-0.27), greater than Virax Biolabs Group Limited (-1.17), greater than Cardio Diagnostics Holdings, Inc. (-0.44), greater than NovaBay Pharmaceuticals, Inc. (-0.99), greater than Oncorus, Inc. (-4.20), greater than eFFECTOR Therapeutics, Inc. (-0.04), greater than Apollomics, Inc. (-0.14), greater than Angion Biomedica Corp. (-0.08), greater than Sigilon Therapeutics, Inc. (-0.24), greater than null (-1.90),

Build a custom stock screener for Humanigen, Inc. (HGEN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Humanigen, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Humanigen, Inc. (HGEN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Humanigen, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Humanigen, Inc.'s PE Ratio?

How is the PE Ratio calculated for Humanigen, Inc. (HGEN)?

What is the highest PE Ratio for Humanigen, Inc. (HGEN)?

What is the 3-year average PE Ratio for Humanigen, Inc. (HGEN)?

What is the 5-year average PE Ratio for Humanigen, Inc. (HGEN)?

How does the current PE Ratio for Humanigen, Inc. (HGEN) compare to its historical average?